Information Provided By:
Fly News Breaks for May 16, 2018
SRDX
May 16, 2018 | 07:21 EDT
Needham analyst Mike Matson raised his price target on Surmodics to $55 after its announcement to acquire Embolitech's thrombectomy technology and associated intellectual property, saying the assets will "further strengthen its whole-product solutions pipeline". Matson also keeps his Buy rating on Surmodics, forecasting its Thrombomatrix share of the $500M thrombectomy market to reach $20M by 2021.
News For SRDX From the Last 2 Days
There are no results for your query SRDX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.